The role of the CEO is subordinate to the board of directors and the CEOs’ main task is to carry out the Company’s ongoing management and the daily activities of the Company. The rules of procedure of the board of directors and the instructions for the CEO stipulate which matters the board shall resolve upon, and which matters fall within the CEOs’ area of responsibility.

Furthermore, the CEO is responsible for preparing reports and necessary information for decision-making prior to board meetings and presents the material at board meetings.

The senior management currently consists of the CEO, Company’s MD, CFO, Head of Regulatory Affairs, Head of Clinical Development, Head of CMC, CMO, CCO, Head of Medical Relations and Head of IR.

Name Position Member of senior Employed in the Holdings in Oncopeptides (1)
management since Company since SH EO O
Jakob Lindberg CEO 2011 2011 235,409 1,070 181,000
Birgitta Ståhl CFO 2016 2016 3,400 91,000
Bengt Gustavsson Head of Medical Relations 2017 2017 600
Elisabeth Augustsson Head of Regulatory Affairs 2015 2015 (2) 1,000 64,000
Eva Nordström Head of Clinical Development 2012 2012 10,000 201 91,000
Fredrik Lehmann Head of CMC 2008 2008 (2) 2,000 79 64,000
Johan Harmenberg CMO 2012 2012 (2) 5,000 160 64,000
Paula Boultbee CCO 2016 2016 (2) 64,000
Rein Piir Head of IR 2016 2016 (2) 2,500 64,000
(1) Refers to shares (“SH”), employee options (“EO”) and options (“O”) held in their own name as well as by affiliated natural and legal persons. Employee options that are vested in accordance with prevailing terms and conditions each entitle to the subscription of 900 shares per option in Company. The options (“O”) entitels to one share in accordance with existing terms. For terms, please read under Corporate Governance/Remuneration.
(2) The assignment is carried out on a consultancy basis.